Fri, January 15, 2021
Thu, January 14, 2021
Wed, January 13, 2021
Tue, January 12, 2021
Mon, January 11, 2021
Sun, January 10, 2021
Fri, January 8, 2021
Thu, January 7, 2021

Joel Beatty Downgraded (SRPT) to Hold and Held Target at $108 on, Jan 12th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. old-and-held-target-at-108-on-jan-12th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Joel Beatty of Citigroup, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Hold and Held Target at $108 on, Jan 12th, 2021.

Joel has made no other calls on SRPT in the last 4 months.



There are 8 other peers that have a rating on SRPT. Out of the 8 peers that are also analyzing SRPT, 4 agree with Joel's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Colin Bristow of "UBS" Downgraded from Strong Buy to Hold on, Monday, January 11th, 2021
  • Danielle Brill of "Raymond James" Downgraded from Buy to Hold on, Friday, January 8th, 2021
  • Martin Auster of "Credit Suisse" Maintained at Hold with Decreased Target to $73 on, Friday, January 8th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $95 on, Friday, January 8th, 2021


These are the ratings of the 4 analyists that currently disagree with Joel


  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $125 on, Friday, January 8th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $135 on, Friday, January 8th, 2021
  • Anupam Rama of "JP Morgan" Downgraded from Buy to Sell and Held Target at $96 on, Friday, January 8th, 2021
  • Chad Messer of "Needham" Maintained at Strong Buy with Decreased Target to $166 on, Friday, January 8th, 2021

Publication Contributing Sources